CoNextions was granted FDA 510(k) clearance to market the CoNextions TR® Tendon Repair System. Expected to launch in May 2022, the novel system addresses traumatic tendon lacerations in the hand, wrist and forearm.
Studies have demonstrated that CoNextions TR supports a strong, fast and smooth repair of tendon lacerations. A prospective randomized clinical trial also showed a lower rate of treatment failure and rupture compared to conventional suture repairs.
“We are pleased with the outcome of FDA’s review of our 510(k) submission supported by a ninety-patient clinical trial, and are excited about the upcoming introduction and commercial launch of the product,” said Jeffrey Barnes, President and CEO of CoNextions.
CoNextions was granted FDA 510(k) clearance to market the CoNextions TR® Tendon Repair System. Expected to launch in May 2022, the novel system addresses traumatic tendon lacerations in the hand, wrist and forearm.
Studies have demonstrated that CoNextions TR supports a strong, fast and smooth repair of tendon lacerations. A prospective...
CoNextions was granted FDA 510(k) clearance to market the CoNextions TR® Tendon Repair System. Expected to launch in May 2022, the novel system addresses traumatic tendon lacerations in the hand, wrist and forearm.
Studies have demonstrated that CoNextions TR supports a strong, fast and smooth repair of tendon lacerations. A prospective randomized clinical trial also showed a lower rate of treatment failure and rupture compared to conventional suture repairs.
“We are pleased with the outcome of FDA’s review of our 510(k) submission supported by a ninety-patient clinical trial, and are excited about the upcoming introduction and commercial launch of the product,” said Jeffrey Barnes, President and CEO of CoNextions.
Copy to clipboard 
